Literature DB >> 19491526

[Central nervous system leukemia mimicking rapidly progressive HTLV-1 associated myelopathy].

Hiroyo Haruki1, Shinichiro Tanaka, Michiaki Koga, Motoharu Kawai, Kiyoshi Negoro, Takashi Kanda.   

Abstract

A 79-year-old woman was suffered from rapidly progressive paresthesia of lower limbs and gait disturbance. After one month, she showed flaccid paraplegia and hyperreflexia in the lower limbs with positive Babinski signs. Anti-HTLV-1 antibody titer was elevated in the serum, but negative in the cerebrospinal fluid (CSF). CSF examination showed mild pleocytosis, elevated protein, and normal glucose content. Adult T cell lymphoma (ATL)-like cells were seen in the CSF. MRI showed no abnormal intensity in the spinal cord and brain. Two months later, she showed rapid worsening of the paraplegia and she became unable to stand. A tentative diagnosis of rapidly progressive HTLV-1 associated myelopathy (HAM) was given, but intravenous methylprednisolone was ineffective. Six months later, she developed pneumonia, and abundant ATL cells were seen in the peripheral blood, suggesting a diagnosis of ATL. Direct infiltration of ATL cells to central nervous system was therefore suggested to have caused neurological abnormalities in this case. One may consider central nervous system leukemia when rapidly progressive HAM-like symptoms and signs are recognized, especially without positive anti-HTLV-1 antibody in the CSF.

Entities:  

Mesh:

Year:  2009        PMID: 19491526     DOI: 10.3143/geriatrics.46.184

Source DB:  PubMed          Journal:  Nihon Ronen Igakkai Zasshi        ISSN: 0300-9173


  1 in total

Review 1.  A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma: A case report and review of the literature.

Authors:  Keiko Tamaki; Hidekazu Mera; Sho Takeshita; Shinsuke Fujioka; Maki Goto; Taichi Matsumoto; Yoshihisa Yamano; Yasushi Takamatsu; Yoshio Tsuboi
Journal:  Medicine (Baltimore)       Date:  2021-10-08       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.